Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Nobias Therapeutics Announces Phase 2 Clinical Trial Results for NB-001 at 52nd Child Neurology Society Annual Meeting


News provided by

Nobias Therapeutics

Oct 10, 2023, 07:00 ET

Share this article

Share toX

Share this article

Share toX

Nobias Therapeutics
Nobias Therapeutics

Trial met its primary endpoint showing NB-001 is safe and well-tolerated; efficacy measures support progression to registrational trial

MOUNTAIN VIEW, Calif., AND PHILADELPHIA, Oct. 10, 2023 /PRNewswire-PRWeb/ -- Nobias Therapeutics, a biotechnology company pioneering AI-based deep phenotyping techniques to discover advanced therapeutics, announced topline data from a Phase 2 clinical trial of NB-001 (fasoracetam), a treatment for the neuropsychiatric symptoms associated with 22q11.2 deletion syndrome ("22q11DS") in children. The data in the late-breaking abstract and poster presentation "A Randomized Double-Blind Placebo-Controlled Phase 2 Clinical Trial of NB-001 (Fasoracetam) for Neuropsychiatric Symptoms in Children with 22q11.2 Deletion Syndrome" were presented at the 52nd Child Neurology Society (CNS) Annual Meeting in Vancouver, BC, on October 5, 2023.

The trial included participants aged 6 to 17 years old with molecularly confirmed 22q11DS and a Clinical Global Impression (CGI)-Severity Scale score of ≥ 4 at screening. The patients also had either (1) psychiatric symptoms in the clinical range for anxiety disorder, attention deficit hyperactivity disorder (ADHD), or autism spectrum disorder, or (2) psychiatric symptoms in the subclinical range for at least 2 out of 3 of these neuropsychiatric disorders. The presence of a history of psychosis was an exclusion criterion for this trial.

Results from the multi-center, randomized, placebo-controlled crossover trial demonstrate the safety and tolerability of NB-001, as well as robust efficacy trends that further support evaluation in a registrational clinical trial.

"We are encouraged by the progress of NB-001 and its potential to help children who have 22q11DS," said Neil Inala, President and CEO of Nobias Therapeutics. "The data further increase our confidence in our NB-001 program, particularly given the small sample size and limited treatment period of this trial. These findings also underscore the value of the genomic dataset and associated electronic health record (EHR) data around which we are building our AI-based deep phenotyping drug discovery engine."

In this crossover trial, patients with 22q11DS received two 6-week treatment periods separated by a 1-week washout period. Each patient was randomly assigned to one of two treatment sequences: NB-001 followed by placebo or placebo followed by NB-001. Evidence from prior studies shows that one mechanistic effect of NB-001 is non-stimulant activation of multiple metabotropic glutamate receptors (mGluRs).

The primary endpoint of the trial was to determine the safety and tolerability of NB-001. The most common adverse events in the 37 patients treated were fatigue and nasopharyngitis in 9 percent of participants, while 6 percent experienced epistaxis, pyrexia, and/or vomiting. All adverse events were graded mild to moderate and there were no serious adverse events attributable to treatment.

The trial's key secondary endpoint was to assess the efficacy of NB-001 using the CGI-Improvement Scale (CGI-I). The least squares mean CGI-I for the treatment period was 3.34 (standard error: 0.15) versus 3.69 (0.15) for placebo (delta=-0.36 (0.20), p=0.07). Investigators further found that NB-001 treatment resulted in improved CGI-I scores for all three symptom groups (ADHD, anxiety, and autism) as compared to their individual baseline scores. Proportionally, the number of patients responding to treatment was 1.4 to 1.7 times higher as compared with placebo. The trial was intended to be signal-finding and therefore was not powered for efficacy endpoint statistical significance.

"Many children with 22q11DS have symptoms of inattention, anxiety, and difficulties with social communication, and very often have symptoms in more than one of these domains. This constellation of symptoms often results in significant functional impairment. The results of this important trial demonstrate that NB-001 holds promise for the high unmet medical need in this patient group and support further clinical development of NB-001 in a registrational-intent Phase 3 clinical trial," said Dr. Bridget Martell, M.D., Advising CMO for Nobias Therapeutics.

About 22q11DS
22q11.2 deletion syndrome ("22q11DS"), also known as DiGeorge syndrome, velocardiofacial syndrome (VCFS), conotruncal anomaly face syndrome, Takao syndrome, and Shprintzen syndrome, is the most common human deletion syndrome and is associated with delayed or incomplete development of several body structures or systems. The syndrome is also strongly associated with neuropsychiatric conditions, including attention deficit hyperactivity disorder (ADHD), anxiety, autism, and schizophrenia/psychosis.

About Nobias Therapeutics
Nobias Therapeutics is a biotechnology company pioneering deep phenotyping to discover advanced therapeutics. Nobias uses its cutting-edge, applied AI platform to distill disease drivers and optimal points for therapeutic intervention from rich clinical and genetic datasets, and to accelerate the development of novel therapies for a broad range of disorders. To learn more, please visit http://www.nobiastx.com and follow Nobias Therapeutics on LinkedIn.

Media Contact

Virgie Townsend, Nobias Therapeutics, 3158026056, [email protected], https://www.nobiastx.com/ 

SOURCE Nobias Therapeutics

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.